NASDAQ:XERS | Free Cash Flow | Xeris Biopharma Holdings, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2020-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31$9.87M
2025-12-31$20.04M
2025-03-31-$10.03M
2024-12-31$1.98M
2024-03-31-$20.3M
2023-12-31$7.47M
2023-03-31-$26.14M
2022-12-31-$16.12M
2022-03-31-$48.41M
2021-12-31-$28.95M$131,000.00-$29.08M
2021-03-31-$23.96M
2020-12-31-$10.87M$225,000.00-$11.09M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31$28.63M
2024-12-31-$36.98M
2023-12-31-$47.02M
2022-12-31-$102.89M
2021-12-31-$95.54M$1.09M-$96.62M
2020-12-31-$80.56M$377,000.00-$80.94M

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.